Lactobacillus acidophilus, LA-5®

Lactobacillus acidophilus, LA-5^® (hereafter referred to by use of the trademark LA-5) as a probiotic has been well studied, with results reported in over 150 scientific publications. 

Chr. Hansen Lactobacillus acidophilus, LA-5^® research shows promise

The bacterial strain Lactobacillus acidophilus, LA-5^® comes from our collection of dairy cultures at Chr. Hansen. It is safe for human consumption; it has been granted QPS (Qualified Presumption of Safety) status from EFSA in Europe.¹ It has been used in food and dietary supplements since 1979.

The LA-5^® strain is a well-researched probiotic that has been described in more than 150 scientific publications. More than 60 of these publications were from human clinical trials that had been run across numerous areas of health. These research studies primarily investigated the LA-5^® strain in combination with the Bifidobacterium, BB-12^® strain. The studies mainly focused on the effect of these probiotic strains in adults and the elderly. 

LA-5^® and BB-12^® are registered trademarks of Chr. Hansen A/S.

The article is provided for informational purposes regarding probiotics and is not meant to suggest that any substance referenced in the article is intended to diagnose, cure, mitigate, treat, or prevent any disease.

Reference list

1. EFSA Panel on Biological Hazards (BIOHAZ). Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 3: Suitability of taxonomic units notified to EFSA until September 2015. EFSA Journal. 2015;13:4331

2. Shioya M, et al. Effect of fermented milk containing Bifidobacterium lactis FK120 on the fecal flora, with special reference to Bifidum species, and fecal properties in elderly volunteers. Journal of Nutritional Food. 2000:33-4.

3. Shioya M, et al. Effect of fermented milk containig Bifidobacterium lactis FK120 on the fecal flora and fecal properties in healthy female volunteers. Journal of Nutritional Food. 2000:18

4. Chatterjee S, et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India. 2013;61(10):708-12. (PubMed)

5. de Vrese M, et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res. 2011;78(4):396-403. (PubMed)

6. Sheu BS, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr. 2006;83(4):864-9. (PubMed)

7. Sheu BS, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16(9):1669-75. (PubMed)

8. Nord CE, et al. Oral supplementation with lactic acid-producing bacteria during intake of clindamycin. Clin Microbiol Infect. 1997;3(1):124-32. (PubMed)

9. Linn YH, et al. Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2019;11(2):638-47. (PubMed)